Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

ABTBullishIndustry Newsnews

High materiality7/10

Abbott Amulet 360 shows strong one-year LAA closure in VERITAS study

Nov 2, 2026, 9:15 AM EST1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

Strong one-year efficacy signals (96.3% closure) and stroke-free rates support ABT's strategic AFib device narrative, though US regulatory status limits immediate revenue upside; history shows clinical data can lift sentiment and multiples even before approvals, yet actual cash flow hinges on US clearance and reimbursement.

AI summary

What happened, with direct paths to the underlying reporting

Abbott reported one-year VERITAS results for Amulet 360 showing durable LAA closure (96.3% zero-leak) and low stroke risk, with over 98% stroke/systemic embolism-free and CV mortality-free at 12 months. CE Mark approval arrived in August 2026; US approval remains investigational, underscoring a regulatory hurdle before near-term revenue realization.

VERITAS: Amulet 360 achieves 96.3% complete LAA closure at 12 months.
Ischemic stroke/systemic embolism-free >98% at one year; mortality-free >98%.
CE Mark approved August 2026; US use is investigational.
Amulet 360 design: softer lobe and outer disc improve sealing across anatomies.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.

Abbott Amulet 360 shows strong one-year LAA closure in VERITAS study

Abbott 2026 growth forecast cut signals ongoing medical device weakness

ABT Eyes Q3 Beat and CardioMEMS Update as Near-Term Catalyst

Barclays starts ABT coverage with Overweight and $120 target

Abbott Laboratories Upgraded to Buy with Higher Target by Rothschild & Co